A Histone deacetylase inhibitor suppresses epithelial-mesenchymal transition and attenuates chemoresistance in biliary tract cancer

49Citations
Citations of this article
57Readers
Mendeley users who have this article in their library.

Abstract

Epithelial-mesenchymal transition (EMT) is involved in the characteristics of malignancy, such as invasion, metastasis, and chemoresistance. In biliary tract cancer (BTC), EMT is induced by transforming growth factor-beta 1 (TGF-β1). The EMT is reversible; therefore, it is conceivable that it could be related to some epigenetic changes. We focused on histone deacetylase (HDAC) inhibitors as regulators of TGF-β1 signaling, and investigated their effect on EMT and chemoresistance. We employed four BTC cell lines (MzChA-1, gemcitabine- resistant MzChA-1, TFK-1, and gemcitabine-resistant TFK-1) and used vorinostat as the HDAC inhibitor. The relative mRNA expression of an epithelial marker (CDH1) and mesenchymal markers (CDH2, vimentin, SNAI1) were measured by qRT-PCR to evaluate factors associated with EMT. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed to evaluate the chemoresistance of each cell line. In addition, NOD/SCID mice were used to evaluate the effect of vorinostat in vivo. In the parent MzChA-1 and TFK-1 cell lines, TGF-β1 induced EMT and chemoresistance; while vorinostat inhibited the EMT and chemoresistance induced by TGF-β1. In gemcitabine-resistant cell lines that highly expressed TGF-β1, vorinostat inhibited EMT and attenuated chemoresistance. We showed that vorinostat inhibits nuclear translocation of SMAD4 which is a signaling factor of TGF-β1, and this is one of the mechanisms by which vorinostat regulates EMT. We also showed that vorinostat attenuates the binding affinity of SMAD4 to the CDH1-related transcription factors SNAI1, SNAI2, ZEB1, ZEB2, and TWIST. Furthermore, combination therapy with vorinostat and gemcitabine improved survival time in the mice xenografted with gemcitabine resistant MzChA-1 cells. In conclusion, vorinostat regulated TGF-β1-induced EMT and chemoresistance through inhibition of SMAD4 nuclear translocation.

References Powered by Scopus

Translating the histone code

8102Citations
N/AReaders
Get full text

Molecular mechanisms of epithelial-mesenchymal transition

6553Citations
N/AReaders
Get full text

Mechanisms of TGF-β signaling from cell membrane to the nucleus

5179Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Mechanisms of TGFβ-induced epithelial–mesenchymal transition

221Citations
N/AReaders
Get full text

Epithelial-to-Mesenchymal Transition: Epigenetic Reprogramming Driving Cellular Plasticity

209Citations
N/AReaders
Get full text

Bcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer

163Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Sakamoto, T., Kobayashi, S., Yamada, D., Nagano, H., Tomokuni, A., Tomimaru, Y., … Mori, M. (2016). A Histone deacetylase inhibitor suppresses epithelial-mesenchymal transition and attenuates chemoresistance in biliary tract cancer. PLoS ONE, 11(1). https://doi.org/10.1371/journal.pone.0145985

Readers over time

‘16‘17‘18‘19‘20‘21‘22‘23‘2406121824

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 17

49%

Researcher 14

40%

Professor / Associate Prof. 3

9%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 18

56%

Medicine and Dentistry 8

25%

Agricultural and Biological Sciences 4

13%

Psychology 2

6%

Save time finding and organizing research with Mendeley

Sign up for free
0